Cellectar Biosciences Inc
Veridion Score
Composite trend over time
Why is CLRB moving today?
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for CLRB.
CLRB insider activity
Cellectar Biosciences Inc
2 insiders bought in the last 90 days
Net buying: $175K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | 2026-05-07 | Longcor Jarrod | Insider | buy | $0.01 | 26,040 | 36,149 | $260 | SEC Form 4 |
| 2026-05-11 | 2026-05-07 | Longcor Jarrod | Insider | buy | $2.88 | 8,680 | 20,451 | $25K | SEC Form 4 |
| 2026-05-11 | 2026-05-07 | CARUSO JAMES V | Insider | buy | $0.01 | 26,040 | 36,076 | $260 | SEC Form 4 |
| 2026-05-11 | 2026-05-07 | CARUSO JAMES V | Insider | buy | $2.88 | 8,680 | 20,318 | $25K | SEC Form 4 |
| 2025-12-16 | 2025-12-12 | NEIS JOHN | Insider | sell | $3.70 | 198 | 10 | $732 | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 6 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moCLRB contract awards, year to date.
Public federal awards linked to this ticker.
CLRB lobbying filings, year to date.
Registered lobbying filings matched to Cellectar Biosciences Inc.